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Abstract
Huntington’s disease (HD) is a fatal neurodegenerative disorder resulting from the
expansion of a trinucleotide repeat within the HD gene. At the cellular level mutant HTT
(mHTT)

aggregates

perturb

cellular

metabolism,

intracellular

trafficking

and

mitochondrial function, resulting in the increased production of reactive oxygen species
(ROS) an event closely linked with nerve cell death. Nuclear factor erythroid 2-related
factor 2 (NRF2) is a redox-sensitive transcription factor responsible for transcribing
neuroprotective genes under the control of the antioxidant response element (ARE),
which work to counteract high intracellular ROS levels. I have identified significant
increases in cell viability, NRF2 nuclear localization, and ARE-luciferase reporter
activity following treatment with the NRF2 activator dimercaptopropanol (DMP). DMP
was also found to increase ARE-directed gene expression and maintain a greater
proportion of functionally active peroxiredoxin 1 (PRX1) protein levels, resulting in
increased neuronal survival. For this reason DMP may serve an important role in treating
HD.

Key Words: HD, ROS, mHTT, NRF2, ARE, DMP Prx1.
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Chapter 1
Introduction
1.1 Preface
Huntington’s disease (HD) is a fatal autosomal dominant genetic disease affecting about
1/30000 individuals in the Canadian population (Jenkins et al. 2005). This disorder is
characterized by progressive neurodegeneration of GABAergic medium spiny neurons in
motor control centres throughout the brain including the caudate nuclei and substantia
nigra as well as cognitive centers in the cerebral cortex and hippocampus (Spokes 1980).
Before the development of movement disorders, HD often initially presents with
psychiatric conditions such as depression, aggression, dementia, memory loss as well as
difficulty with judgement and problem solving skills (Duff et al. 2007). HD-associated
neurodegeneration results in motor coordination deficits leading to loss of muscle control
throughout the body (Young et al. 1986). Individuals with HD experience muscle
weakness and incoordination in facial and pharyngeal muscles, (lips, tongue and
esophagus) resulting in dysarthria and difficulty in orchestrating the correct sequence of
muscle movements necessary for speech (apraxia; Hartelius et al. 2010). Additionally HD
patients suffer from dysphagia, specifically involving a delayed or intermittent swallow
reflex as well as an inability to coordinate swallowing with speaking or breathing
(Leopold and Kagel 1985). The leading causes of death in HD patients are aspiration
pneumonia resulting from dysphagia; and congestive heart failure due to the weakening
of cardiac muscles (Heemskerk and Roos 2010). The third-leading cause of death in HD
patients is suicide, which can likely be attributed to HD-associated psychiatric
disturbances and a bleak prognosis (Heemskerk and Roos 2010). There is no cure for HD
and the treatments available to those suffering with the disease serve only to manage the
most troublesome symptoms. Mood stabilizing drugs such as lithium and valproic acid
are combined with antidepressants such as fluoxetine to manage psychiatric disorders
associated with HD (Chiu et al. 2011). Antipsychotics such as haloperidol are combined
with tetrabenazine in order to suppress the writhing and involuntary movements; however
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these treatment regimens often exacerbate the psychiatric symptoms and are associated
with unpleasant side-effects (Gimenez-Roldan and Mateo 1989).

1.2 Molecular Basis of HD
HD is caused by a CAG trinucleotide repeat expansion in exon 1 of the HD gene, which
results in a polyglutamine (polyQ) repeat expansion in the encoded Huntingtin (HTT)
protein (Landles and Bates 2004). The polyQ domain of HTT is highly polymorphic and
an extended polyQ repeat confers an increased tendency of mHTT to aggregate, leading
to the formation of neurotoxic intracellular inclusion bodies (Landles and Bates 2004).
Accordingly, there is a strong negative correlation between repeat length and age at
onset; and a positive correlation between repeat length and severity of the disease
(Landles and Bates 2004). A repeat tract of <35Q is considered non-pathogenic and
individuals carrying 35-40Q exhibit intermediate penetrance of the disease (Landles and
Bates 2004). Repeat tracts in excess of 40Q invariably result in adult-onset HD while
repeats in excess of 100Q give rise to childhood onset HD and represent the most
aggressive manifestation of the disease (Landles and Bates 2004). Interestingly, the
polyQ motif forms a polar zipper structure which is known to facilitate HTT association
with transcription factors that also contain a polyQ region (Suagrs and Rubinsztein 2003).
The wild-type HTT protein is ubiquitously expressed throughout the nervous system and
is necessary for embryogenesis and brain development in mice (Zeitlin et al. 1995). HTT
knockout mice (Hdh

-/-

) exhibit embryonic lethality before gastrulation at day 8.5;

whereas HTT knockdown mice (<50%) exhibit aberrant neurogenesis and deformities in
the cerebral cortex, striatum and hippocampus (Zeitlin et al. 1995). Although the wildtype function of HTT remains poorly defined, it has been putatively identified as a
scaffold protein and mediator of endocytic vesicular transport, interacting with clathrin,
HTT-interacting proteins (Hips) and HTT-associated proteins (Haps; Pal et al. 2006).
RNAi knockdown of HTT in post-mitotic D. melanogaster neurons results in vesicle and
mitochondrial trafficking deficits, and overexpression of HTT has been demonstrated to
be neuroprotective against serum starvation and mitochondrial insults in mouse striatal
neurons (Bossy-Wetzel et al. 2008). HTT is suspected to be involved in intracellular
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trafficking based on the association of HTT with endosomal compartments,
Dynein/Dynactin motors, and microtubules; as well as the presence of both nuclear
export and nuclear localization signals near the HTT C-terminus (Li et al. 1998; Xia et al.
2008). Phosphorylation and dephosphorylation of HTT appear to regulate anterograde
and retrograde axonal transport, respectively in mammals (Zala et al. 2008). Interestingly,
HTT is believed to be neuroprotective through inhibition of caspase 9 activation and
increased levels of HTT are able to mitigate the effects of the mutant protein (mHTT) in a
dose-dependent manner, suggesting that HD pathogenesis may be in part due to loss of
endogenous HTT function (Rigamonti et al. 2001).
mHTT undergoes a toxic gain-of-function which not only promotes novel protein-protein
interactions, but also confers a tendency of the protein to self-associate and form
oligomeric aggregates and ultimately large protein inclusion bodies (Fox et al. 2011).
This toxic gain-of-function is strictly dependent on mHTT cleavage by caspase 6, and
covalent cross-linking by transglutaminase 2, generating mHTT N-terminal oligomers
(Graham et al. 2006; Zainelli et al. 2005). Initially the smaller mHTT oligomers remain
soluble in the cytoplasm, interfering with axonal transport, neurotransmission,
mitochondrial activity and transcriptional regulation (Fox et al. 2011). When cytoplasmic
mHTT levels rise beyond a critical concentration they rapidly coalesce forming a large
perinuclear protein inclusion body, believed to be partially neuroprotective through
sequestration of the highly toxic oligomers (Ossato et al. 2005). mHTT is ubiquitinated
by E3 ligases but there is evidence that it interferes with and/or overwhelms proteasome
activity, leading to mHTT accumulation in the cytoplasm (Subramaniam et al. 2010).
mHTT is also sumoylated by the striatal-specific protein RHES, which increases its
solubility and cytotoxicity, possibly contributing to the selective nature of
neurodegeneration in HD, with the effects of mHTT being most severe in striatal neurons
(Subramaniam et al. 2010).

In addition to acting as physical roadblocks, mHTT

oligomers interfere with axonal trafficking by binding the anterograde motor kinesin and
retrograde motor dynactin, effectively paralyzing microtubule-associated transportation
(Zala et al. 2008). Neurons are highly dependent on vesicle and organelle transport for
proper neurochemical and electrical signalling, and medium spiny neurons may be
particularly susceptible to mHTT toxicity as a result of their extensive dendritic processes
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(Trushina et al. 2004). Not only does mHTT affect neuronal physiology, but it also causes
non-specific transcriptional repression, through its direct binding to RNA polymerase II
subunits and global gene silencing through its inactivation of histone acetyltransferases
(Anderson et al. 2008). mHTT additionally undergoes specific interactions with
transcription factors such as p53, NF-kB, and SP1 (Ravache et al. 2010). Wild-type HTT
has been demonstrated to upregulate brain-derived neurotrophic factor (Bdnf) mRNA –
encoding a key growth factor for the survival and synaptic regulation of striatal neurons,
HTT also stimulates BDNF vesicular transport; while mHTT expression or HTT
knockdown diminishes this effect (Toro et al. 2006).

1.3 Mitochondrial Dysfunction in HD
Oxidative stress is a hallmark feature of HD and several molecular markers of oxidative
stress have been identified in post mortem analysis of human brains, such as peroxidized
unsaturated fatty acids, nitrated proteins and hydroxylated nucleic acids (Ischiropoulos
and Beckman 2003). Reactive oxygen species (ROS) are the primary mediator of
oxidative stress, and are generated by the unequal transfer of electrons to molecular
oxygen, particularly during oxidative phosphorylation in the mitochondria (Ischiropoulos
and Beckman 2003). mHTT oligomers directly interfere with mitochondrial membrane
potential and function by binding and depolarizing the mitochondrial membrane, which is
believed to be facilitated by contact between the mitochondria and the mHTT polyQ
motif (Bossy-Wetzel et al. 2008). Depolarization of the mitochondrial membrane causes
opening of the permeability transition pore (PTP) and the release of cytochrome C, which
proceeds to associate with the apoptosome and trigger cell-autonomous apoptotic
signalling and neuronal cell death (Bossy-Wetzel et al. 2008). mHTT also binds and
inhibits complex II of the electron transport chain as well as mitochondrial fission and
fusion regulators such as dynamin related peptide (DRP1) and mitofusin (MF1), which
results in mitochondrial stress and a net increase in the generation of ROS (Jana et al.
2001; Olivera 2010).
The mHTT protein also interferes with mitochondrial function indirectly through
inhibition of peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α),
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which is a transcriptional regulator of genes involved in mitochondrial biogenesis,
respiration and oxidative stress defense (Bossy-Wetzel et al. 2008; Lin et al. 2004). There
is evidence that mHTT binds and inactivates the cAMP response element binding protein
(CREB) transcriptional activator, resulting in reduced expression of PGC-1α and its
effectors such as nuclear respiration factor-1 (NRF1; Bossy-Wetzel et al. 2008). PGC-1α
knockout experiments in mice reveal strikingly similar patterns of neurodegeneration to
HD and studies using transgenic mice expressing mHtt demonstrated a notable reduction
in PGC-1α protein levels, which was most pronounced in medium spiny neurons as
compared with interneurons (Lin et al. 2004; Neumann and Cao 2008). This leads to the
hypothesis that HD-induced loss of PGC-1α may be a contributor to the selective nature
of striatal-specific neurodegeneration observed in HD (Cui et al. 2006). Medium spiny
neurons may also be more susceptible to mHTT-induced toxicity than other neuron types
as a result of their high energetic demands and long projections to other regions of the
brain rendering them particularly sensitive to mitochondrial function and trafficking
defects (Bossy-Wetzel et al. 2008).

1.4 NRF2 and the Antioxidant Response Element
Although mitochondrial insults can sensitize neurons to apoptosis, there are ROS
scavenging enzymes that work to counteract oxidative stress by serving as competitive
oxidative targets (Neumann and Cao 2009). Peroxiredoxin 1 (PRX1) is a ubiquitous
intracellular antioxidant protein that serves a neuroprotective role through its capacity to
attenuate ROS levels by undergoing redox cycling via sulfhydryl groups associated with
its catalytic cysteine residue (Figure 1; Nuemann and Cao 2009). This residue permits
PRX1 to form intermolecular disulphide-bridged dimers while simultaneously reducing
hydrogen peroxide or oxygen radicals to water (Cumming et al. 2007). Thioredoxin
(TRX) and thioredoxin reductase (TRXR) are enzymes that work in concert to reduce the
disulphide-bridged PRX1 dimers, reactivating the monomers and resetting the redox
cycle (Cumming et al. 2007). However, the detoxifying capabilities of PRX1 can be
overwhelmed by excessive ROS generation leading to further oxidation of the cysteineassociated thiol (-SH) group to a sulfenic acid (-SOH) species (Cumming et al. 2007).
Under extreme oxidative stress the sulfenic acid is oxidized to sulfinic acid (-SOOH) and
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ultimately sulfonic acid (-SOOOH; Cumming et al. 2007). These inactive hyperoxidized
PRX1 monomers are consequently polyubiquitinated by E6-associated protein (E6AP)
and degraded by the proteasome (Cumming et al. 2007). PRX1 protein levels decrease
following mHtt expression in a PC12 nerve cell model, while overexpression of wildtype, but not a catalytically inactive PRX1 variant, can partially suppress mHTT toxicity;
suggesting that a compromised antioxidant defense may play a role in potentiating HD
pathophysiology (Pitts et al. 2012). However, the mechanism by which mHtt expression
decreases PRX1 levels is currently unknown. The antioxidant response element (ARE) is
a regulatory enhancer sequence present in the promoters of many antioxidant genes (i.e.
Prx1 and Trx/TrxR) as well as Phase II detoxifying genes i.e. glutatione-S-transferase
(Gst) and heme oxygenase (HO); and is positively regulated by nuclear factor erythroid 2related factor 2 (NRF2) in response to oxidative stress (He and Ma 2010). NRF2 is a
redox-sensitive transcription factor, which is normally sequestered in the cytoplasm by Factin-bound Kelch-like ECH-associated protein 1 (KEAP1) resulting in E3 ligasemediated polyubiquitination of the complex and subsequent proteosomal degradation
(Furukawa and Xiong 2005; Taguchi 2010). Under oxidative stress conditions, critical
cysteine residues associated with the KEAP1 redox-sensing domain are oxidized, causing
a conformational change such that KEAP1 is no longer capable of binding NRF2
(Furukawa and Xiong 2005). This results in the translocation of NRF2 into the nucleus
via importin α, where it binds the transcriptional co-activator musculoaponeurotic
fibrosarcoma oncogene homolog (MAF) and initiates transcription of ARE-associated
genes (Figure 2; Furukawa and Xiong 2005). Additional transcriptional co-factors are
required for normal expression of ARE-directed gene expression; for example the
regulatory regions of HO and Gst have multiple Activating Protein 2 (AP-2) and
Specificity Protein 1 (SP1) binding sites, and are dependent on these factors for high
levels of expression (Lavrovsky et al. 1994; Moffat 1996). Interestingly, SP1 interacts
specifically with polyglutamine protein motifs and has been demonstrated to bind the
mHTT polyglutamine region in vivo, suggesting that mHTT not only causes a destructive
increase in ROS levels, but may simultaneously compromise an appropriate antioxidant
transcriptional response (Trushina et al. 2003). In addition to controlling antioxidant
genes, NRF2 also undergoes AP-2/SP1-dependent autoregulation of its own expression
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(Chan et al. 1996). Hence, the potential effect of mHTT-SP1 interactions may lead to
decreased expression of ARE genes, including Nrf2, effectively crippling the cell’s
antioxidant response. Chemical compounds which form adducts with KEAP1 such that
the KEAP1/NRF2 complex can no longer assemble mimics oxidative activation of NRF2
and results in stabilization and translocation of NRF2 into the nucleus (He and Ma 2010).
Chemical augmentation of NRF2 by KEAP1 inhibition using Carnosic acid or
triterpenoid derivatives has yielded promising evidence that increasing ARE-directed
gene expression can attenuate toxicity in HD (Stack et al. 2010; Yang et al. 2009). Since
excessive oxidative stress is directly related to pro-apoptotic cellular programmes and
ultimately neurodegeneration in HD, chemicals that inhibit KEAP1 and promote NRF2
transcriptional activity may boost the antioxidant response and increase the longevity and
functionality of HD-affected neurons (He and Ma 2005).

1.5 2,3-Dimercaptopropanol
2,3-Dimercaptopropanol (DMP) was first synthesized in 1940 under the pseudonym
British anti-lewisite (BAL) and was implemented as an antidote to the neurotoxic
chemical weapon Lewisite (C2H2AsCl3; Pavlic et al. 1949). Arsenic and other heavy
metals react with important metabolic enzymes such a pyruvate dehydrogenase (PDH) by
chemically interacting with adjacent thiol groups forming a chelate that inactivates the
enzyme, leading to lactic acidosis and apoptosis (Petrick et al. 2001). DMP’s utility in
counteracting heavy-metal toxicity arises from its adjacent thiol groups, which serve as
an alternative target for the toxic metal (Vilensky and Redman 2003). As a result of its
thiol-mediated heavy-metal chelating properties, DMP has been effective in preventing
systemic arsenic poisoning associated with Lewisite exposure (Vilensky and Redman
2003). DMP has also been administered to treat high copper levels associated with
Wilson’s Disease, and is still used today in treating lead, mercury and gold poisoning
(Vilensky and Redman 2003). Consequently, DMP was evaluated as a HD treatment for
its heavy metal chelating properties in the early 1950s when HD was also believed to be
caused by excessive copper accumulation in the brain (Vilensky and Redman 2003).
Administration of DMP to two HD patients by intramuscular injection over the course of
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Figure 1. PRX1 detoxifies ROS by undergoing redox cycling. PRX1 is able to reduce
oxidized functional groups (i.e. ROOH) by reacting with other PRX1 monomers via a
reactive cysteine residue, which results in the elimination of water and the formation of
disulphide-bridged PRX1 dimers. Trx reduces these dimers back to their catalyticallyactive monomeric state using NADPH reducing equivalents. If intracellular ROS levels
exceed the tandem reductive capabilities of PRX1 and TRX, the catalytic cysteine residue
becomes progressively oxidized to a sulfenic, sulfinic and ultimately sulfonic acid; an
irreversible event leading to the degradation of PRX1 by the proteasome. Image kindly
provided by Dr. Robert Cumming.
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Figure 1
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Figure 2. NRF2 Regulation by Oxidative Stress. In the cytoplasm NRF2 remains in
complex with KEAP1 resulting in polyubiquitination and degradation of both proteins. If
sufficient oxidative stress exists in the cell, redox-sensing KEAP1 cysteine residues are
oxidized resulting in the dissociation of the NRF2/KEAP1 complex, and the subsequent
translocation of NRF2 into the nucleus. In the nucleus, NRF2 binds the ARE in its target
gene promoters (i.e. Prx1, HO and Nrf2) and enhances transcriptional activity.
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Figure 2
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a year led to a dramatic reduction of HD symptoms, but was discontinued due to practical
difficulties in administering the drug as well as pain and abscesses at the injection site
(Nielsen and Butt 1955). Furthermore, a subsequent study of a broader number of HD
patients revealed copper levels that were normal, indicating that a copper imbalance does
not contribution to HD pathogenesis (Campbell et al. 1961).In a blind screen of 1040
FDA approved compounds, which suppressed mHTT-induced toxicity in a rat PC12 cell
model, DMP was identified as a strongly neuroprotective agent, but was largely
disregarded by the authors (Aitken and Schweitzer 2004). DMP has further been
established as a potent inhibitor of KEAP1, forming S-alkylation adducts with the protein
such that it dissociates from NRF2, permitting NRF2 nuclear translocation and
transcriptional activity (He and Ma 2010). Interestingly, treatment of PC12 cells with
DMP prevents loss of PRX1 protein following expression of mHtt-103Q and increases
cell viability (Pitts et al. 2012). The precise mechanism by which DMP exerts
neuroprotection in an HD context remains unknown, but because PRX1 is a downstream
effector of NRF2 it stands to reason that the neuroprotective properties of DMP may be
mediated by NRF2 stabilization (Figure 3; Kim et al. 2007). A more broad understanding
of DMP’s effect on NRF2 and its effectors will be useful for future HD drug discovery as
well as the exploration of other potential therapeutic targets to ameliorate the disease.

1.6 Hypothesis and Investigational Plan
It is hypothesized that expression of mHtt will interfere with NRF2-dependent AREdirected gene expression (i.e. Prx1) thereby exacerbating oxidative stress in the cell.
DMP counters this effect by triggering NRF2 nuclear translocation and increased AREdirected gene expression. This study aims to determine the mechanisms by which DMP,
and possibly other NRF2-activating compounds, exert a neuroprotective effect on mHTTinduced toxicity using a PC12 nerve-cell line capable of inducible expression of mHtt. It
will be important to determine if loss of PRX1 protein is correlated with mHTT toxicity.
Additionally, I will determine if ectopic expression of PRX1 correlates with
neuroprotection against mHTT toxicity. I will also investigate the effect of mHtt
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expression and DMP treatment on NRF2 subcellular localization and PRX1 oxidation
state, as well as ARE gene transcript levels. To establish whether or not NRF2 activation
plays a role in DMP-mediated neuroprotection, I will use an NRF2-responsive ARELuciferase reporter construct to quantify levels of NRF2 transcriptional activity following
either DMP treatment or induced expression of mHtt.
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Figure 3. Hypothesized mechanism by which DMP confers neuroprotection. DMP is
believed to form chemical adducts with KEAP1, changing the conformation of the
protein or blocking its association with NRF2, resulting in NRF2 nuclear translocation
and transcriptional activity.
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Figure 3
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CHAPTER 2
Materials and Methods
2.1 Cell Culture Conditions
PC12-103Q-GFP cells were obtained from Leslie Thompson (UC Irvine, CA) and
maintained in DMEM (Biowhittaker) supplemented with 10% Horse Serum (HS), 5%
Fetal Bovine Serum (FBS) and 1% penicillin/streptomycin at 37•C in a humidified CO2
incubator with 5% CO2/95% air. These cells are stably transfected with a plasmid
encoding exon 1 of the HD gene with a pathogenic 103Q repeat fused in frame to the
coding sequence of enhanced GFP at the carboxy terminus, under the control of an
inducible ecdysone promoter. Transcription of the transgene was activated by treating
cells with 2.5 µM Tebufenozide (an ecdysone analogue) in the culture medium. This cell
line exhibits rapid (48h) and extensive (>50%) cell death after induction of mHtt-103Q
expression.

2.2 PRX1 expression plasmids and transfection
Expression constructs containing FLAG-tagged versions of both wild type (WT) and
cysteine mutant (C52S) Prx1 cDNAs cloned into pcDNA 3.1 were generously supplied
by Dr. Hyunjung Ha (Chungbuk National University, Cheonju Korea). PC12-Htt-103QGFP cells were seeded in 35-mm dishes at 3 x 105 cells/dish and co-transfected with
either pcDNA or FLAG-tagged PRX1 expression constructs along with a mCherry
Fluorescent Protein reporter plasmid at a 3:1 molar ratio for a total of 4 μg of DNA per
dish using Lipofectamine 2000 (Invitrogen) in Opti-MEM media. Plasmid DNA mixed
with 4 μl of Lipofectamine 2000 in Opti-MEM media was added to PC12 cell cultures,
and 6 h later the transfection media was replaced with DMEM containing 10% HS and
5% FBS. The following day, transfected cells were treated with 2.5 μM Tebufenozide to
induce mHtt expression and at 48 hours post-induction, cells were trypsinized and scored
for cell viability by trypan blue dye exclusion using a hemocytometer and both light and
epifluorescent microscopy. Viability in successfully transfected cells was assessed by
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comparing the average number of mCherry positive (successfully transfected) and trypan
blue negative (living) cells after Tebufenozide induction, versus cells transfected with the
same plasmid, but without Tebufenozide treatment. This indicates the extent to which the
plasmid confers neuroprotection in the presence of mHTT expression. Mean cell viability
ratios from three independent experiments were analyzed using a one way ANOVA and
post-hoc Tukey test.

2.3 MTT Cell Viability Assays
For MTT cell viability assays PC12 Htt-103Q-GFP cells were seeded in quadruplicate at
7 x 103 cells/well in 96-well plates (100 μl total culture volume). DMP as well as
structurally related compounds 3-mercaptopropanol (3MP) and glycerol, in addition to
ARE-activators 1,2-Dithiole-3-thione (D3T), Oltipraz, tert-Butylhydroquinone (tBHQ)
and Carnosic acid (Figure 5A) were added at various concentrations (1, 5, 10, 50 and 100
μM) to 96-well plates 24 h after seeding cells. One hour after compound exposure,
transgene expression was induced with 2.5 μM Tebufenocide. 48 hours after induction of
mHtt-103Q-GFP expression 10 μL of a 5 mg/ml MTT solution prepared in PBS was
added to the culture media and incubated at 37oC for two hours. Media was thoroughly
aspirated from the wells and rinsed twice with PBS; the purple formazan product of MTT
was released from cells by the addition of 100 μL of DMSO. Absorbance was measured
at a test wavelength of 595 nm and reference wavelength of 655 nm using a BioRad 3550
microplate reader. Mean cell viability ratios from three independent experiments were
analyzed using a one way ANOVA and post-hoc Tukey test.

2.4 RT-PCR
RNA was extracted from PC12 cells using TRIzol reagent (Invitrogen) following the
manufacturer’s protocol. Briefly, 1 μg total RNA was reverse transcribed into cDNA
using a 1st Strand cDNA Synthesis kit (Quanta BioSciences Inc). RT-PCR was
performed using a mastercycler thermocycler (Eppendorf) for 30 cycles for Prx1 and 27
cycles for GAPDH as a control. Each cycle included denaturation at 94°C for 20s,
primer-specific annealing temperatures for 45s and elongation at 72°C for 45 s. The
primers used for Prx1 were For– 5’CCTGTAGCTCGACTCTGCTGATAG3’ and Rev–
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5’ GCGGCCAACAGGAAGATC 3’ with an annealing temperature of 57°C (Jiang and
Stefanovic 2008),

for GAPDH were For- 5’CCTTCATTGACCTCAACTAC3’, and

Rev–5’GGAAGGCCATGCCAGTGAGC3’ with an annealing temperature of 64°C (Lee
et al. 2009), for HO were For- 5’GGGTGACAGAAGAGGCTAAGACC3’ and Rev5’AGATTCTCCCCTGCAGAGAGAAG3’ with an annealing temperature of 60°C
(Scapagnini

et

al.

2002)

5’TTCCTCTGCTGCCATTAGTCAGTC3’

and

for

Nrf2

were

and

ForRev-

5’GCTCTTCCATTTCCGAGTCACTG3’ with an annealing temperature of 55°C (Ikeda
et al. 2000). Each primer set was run at 28, 30 and 32 cycles to verify that amplification
was occurring only within the resolvable linear range. The size of the PCR products was
determined by 1% agarose gel electrophoresis with visualization by ethidium bromide
staining. Amplicon band intensity was analyzed by ImageJ software and expressed
relative to GAPDH band intensity. Mean relative band intensity from three independent
experiments were analyzed using a one way ANOVA and post-hoc Tukey test.

2.5 Subcellular Fractionation and SDS PAGE/Immunoblot
For nuclear/cytoplasmic subcellular fractionation, PC12 Htt-103Q-GFP cells were seeded
on 10 cm dishes at 1.5 x 106 cells/dish. Cells were treated with 100 µM DMP, 2.5 µM
Tebufenozide, or 100 µM DMP + 2.5 µM Tebufenozide for 0, 24, 48 and 72 hours
respectively. Cells were then washed with PBS and centrifuged at 800 x g for 1 minute in
an Eppendorf 5415R centrifuge and resuspended in 100 µL of hypotonic lysis buffer (20
mM Tris-HCl; pH 7.4, 10 mM NaCl, 3 mM MgCl2). Cells were then incubated on ice for
15 minutes and lysed using 10 µL of 10% NP-40 (Sigma), and centrifuged at 6000 x g for
5 minutes. The cytoplasmic supernatant was transferred to a separate tube and the nuclear
pellet was washed twice in hypotonic lysis buffer + 1% NP-40 and resuspended in 100
µL of SDS lysis buffer (50 mM Tris pH 7.5, 2% SDS, 1 mM PMSF and 10 mM
iodoacetamide). Protein extracts (30 μg) were treated with 100 mM DTT and 2% βmercaptopropanol (BME), boiled for 5 min and then resolved by 12% PAGE using a
BioRad electrophoresis apparatus. Gels were electroblotted onto Immobilon-P membrane
(Millipore, Bedford, MA), blocked with 1% milk and 3% BSA (Sigma) in Tris-buffered
saline with 0.5% Tween-20 (TBS-T). Membranes were incubated overnight with
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polyclonal rabbit antibodies against NRF2 (Santa Cruz Biotechnology), Prx-1
(AbFrontier), sulfonylated Prx (AbFrontier), GFP (Sigma), Actin (Cell Signaling) or
Histone H3 (Cell Signalling). Following incubation, membranes were washed with TBST and further hybridized with horse-radish peroxidase-conjugated goat anti-rabbit
secondary antibodies (BioRad). Detection was performed using Pierce ECL Western
blotting detection reagents (ThermoScientific) and visualized using a ChemiDoc digital
imaging system (BioRad). Densitometric analysis was performed using ImageJ software
and expressed relative to actin. Mean relative band intensity from three independent
experiments were analyzed using a one way ANOVA and post-hoc Tukey test.

2.6 Luciferase Assay
For the ARE-Luciferase assay, PC12 Htt-103Q-GFP cells were seeded in 12-well dishes
at 1.3 x 105 cells/well and transfected with 2 µg of the ARE-Luciferase reporter plasmid
(Numazawa et al. 2003) as well as 0.2 µg of pRL-TK Rinella Luciferase control plasmid
(Promega), using 25 µL of Lipofectamine 2000 (Invitrogen) in Opti-MEM media per
well. After 6 hrs, the transfection media was replaced with DMEM containing 10% HS
and 5% FBS and 18 hours post-transfection cells were treated with 100 µM DMP, 2.5
µM Tebufenozide, or 100 µM DMP + 2.5 µM Tebufenozide for 0, 24, 48 and 72 hours
respectively. Luciferase assays were carried out using a Dual-Luciferase® reporter assay
system (Promega), bioluminescence was measured using the Infinite® M1000 PRO
microplate reader (Tecan). To control for transfection efficiency ARE-associated Firefly
Luciferase was expressed relative to control Rinella Luciferase bioluminescence; this
ratio was further expressed as a fold change from the 0 hour timepoint for each treatment.
Mean relative Luciferase activity from three independent experiments was analyzed using
a one way ANOVA and post-hoc Tukey test.

20

Chapter 3
Results
3.1 Prx1 Overexpression Increases Cell Viability
Increased expression of mHtt promotes neurotoxicity and loss of Prx1 expression (Pitts et
al. 2012); therefore, it was of interest to determine if overexpression of Prx1 could
protect against mHTT-induced toxicity. In addition, to evaluate whether any observed
neuroprotective effect is strictly dependent on PRX1 antioxidant activity or an alternative
mechanism, both wild-type (PRX1-WT) and a catalytically-inactive (PRX1-C52S)
cysteine mutant PRX1 were overexpressed. PC12-103Q-GFP cells transfected with a
pcDNA 3.1 control vector and induced to express mHtt with Tebufenozide for 48 hours
underwent a loss of endogenous PRX1, as well as a 37% decrease in cell viability (Figure
4). Similarly, PC12-103Q-GFP cells expressing the catalytically inactive C52S PRX1
mutant exhibited toxicity comparable to that of control transfected cells following
induction of mHtt expression (Figure 4). In contrast, PC12-103Q-GFP cells
overexpressing Flag-tagged wild-type PRX1 species demonstrated a statistically
significant increase in viability following induction of mHtt compared to control
transfected cells (Figure 4).

3.2 Effect of Potential ARE Activators on mHTT Toxicity
DMP exposure prevents loss of PRX1 protein levels and suppresses cell death in mHtt
expressing PC12 cells (Pitts et al. 2012). Maintenance of PRX1 protein has further been
correlated with increased viability following mHtt expression in PC12 cells (Figure 4).
PRX1 expression is controlled, in part, by the transcription factor NRF2 binding to ARE
elements within its promoter regions (Taguchi 2010).

It was therefore of interest to

evaluate the relative neuroprotective effects of DMP and its structural variants, as well as
bona fide ARE-activating compounds in a HD context (Figure 5A). Treatment with DMP
structural variants glycerol and 3MP did not yield any appreciable increases in cell

21

Figure 4. Maintenance of wild-type Prx1 expression attenuates mHTT toxicity.
Western blot analysis demonstrated that 48 hours post-mHtt induction PC12-103Q-GFP
cells transfected with a pcDNA 3.1 control plasmid or catalytically inactive (PRX1C52S) PRX1 undergo a loss of endogenous PRX1, which correlates with a decreased in
cell viability. Overexpression and maintenance of Flag-tagged wild-type PRX1 (PRX1WT) correlates with a statistically significant increase in cell viability (*, P<0.01,n=3).
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Figure 5. DMP and D3T treatment attenuates mHtt toxicity. MTT viability assays
conducted on PC12-103Q-GFP cells treated with DMP and the structurally related
compounds 3MP and glycerol; as well as ARE-activating compounds D3T, Oltipraz,
tBHQ and Carnosic acid (A). Chemical structures were obtained from the PubChem
project (ID#s 3080, 88211, 753, 68296, 47318, 16043 and 65126, respectively). Drug
treated cells were induced to express mHtt with Tebufenozide and survival was measured
at 48 hours post-induction (B; *, P<0.05; **, P<0.01, n=3).
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Figure 5 (A)
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viability. Treatment with the ARE-activating compounds Oltipraz, tBHQ and Carnosic
acid treatment resulted in modest, but not statistically significant increases in cell
viability following expression of mHtt (Figure 5B).

However, treatment with the

compound D3T (also an ARE-activator) resulted in statistically significant increases in
cell viability following expression of mHtt (Figure 5B). Interestingly, DMP treatment
resulted in the highest level of protection against mHTT toxicity (Figure 5B).

3.3 ARE-Directed Gene Expression is Affected by DMP and mHTT
Loss of PRX1 expression correlates with mHTT-induced neurotoxicity (Figure 4), but
whether this occurs at the transcriptional or post-translational level following mHtt
expression is unknown. Since Prx1 is regulated by NRF2 via the ARE, three AREregulated transcripts (Prx1, HO and Nrf2) were chosen for examination by semiquantitative RT-PCR at 0, 24, 48 and 72 hour time points under control, Tebufenozide,
DMP and DMP + Tebufenozide treatments. In the untreated control Prx1 and HO
transcript levels remain constant, while Nrf2 transcript levels oscillate (Figure 6A, C-E).
Following expression of mHtt using Tebufenozide , there is a statistically significant
reduction in HO and Nrf2 transcript levels at 24, 48 and 72 hour time points (Figure 6C,
E) as well as a significant loss of Prx1 transcript at 24 and 48 hours post-treatment
(Figure 6D). It was also important to ascertain whether the protective effect associated
with DMP treatment was mediated by ARE transcriptional activation or if PRX1 protein
maintenance was rather the result of a post-translational mechanism. Indeed, DMP
treatment resulted in statistically significant increases in HO and Nrf2 transcript levels at
24 and 48 hours (Figure 6C, E) as well as a significant increase in Prx1 transcript levels
at 72 hours (Figure 6D). DMP + Tebufenozide treatment resulted in statistically
significant increases in HO transcripts at 24 and 72 hours post-treatment (Figure 6C), as
well as maintenance of Prx1 and Nrf2 transcript levels (Figure 6D, E) throughout the
course of the experiment.

3.4 Western Blot Analysis of Prx1 and Nrf2
To determine if the transcriptional changes associated with mHtt expression and DMP
treatment also resulted in changes in protein expression, Western blot analysis was
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Figure 6. Semi-quantitative RT-PCR Analysis of ARE-Directed Gene Expression.
PC12-103Q-GFP cells were treated with Tebufenozide (A), DMP (B) or Tebufenozide +
DMP (B) for 0, 24, 48 and 72 hours. Transcripts were detected using HO, Prx1, Nrf2 and
GAPDH specific primers. Densiometric analysis of band intensity is shown for HO (C),
Prx1 (D) and Nrf2 (E) relative to GAPDH. Statistically significant changes in gene
expression in treated relative to untreated cells are indicated (*, P<0.05; **, P<0.01, n=3).
Each time point was compared relative to the 0H control and no between-treatment
comparisons were made. The use and adaptation of figures 6(A) and 6(B) has been done
with permission by the copyright holder © 2012 by The American Society for
Biochemistry and Molecular Biology, Inc.
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Figure 6 (A)
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Figure 6 (C)

(D)

(E)
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performed on protein extracts using PRX1- and NRF2-specific antibodies. Protein
expression profiles were analyzed in untreated (Figure 7A), Tebufenozide (Figure 7B),
DMP (Figure 7C) and DMP + Tebufenozide (Figure 7D) treated PC12-103Q-GFP cells.
Since mHTT is fused to GFP in PC12-103Q-GFP cells, a GFP antibody was used to
measure mHTT levels; extremely low levels of GFP were detected in control and DMP
treated samples, while dramatically higher levels were found in Tebufenozide and DMP
+ Tebufenozide treated cells (Figures 7A-D). Cell extracts were also fractionated into
cytosolic and nuclear fractions in order to compare the relative nuclear localization of
NRF2 as cytoplasmic NRF2 is rapidly degraded. NRF2 levels in the cytoplasm and
nucleus remained relatively uniform in untreated cells, however with Tebufenozide
treatment cytoplasmic NRF2 levels underwent a statistically significant increase after 48
hours, whereas nuclear NRF2 levels were modestly decreased at 6, 24 and 48 hour time
points (Figure 8). DMP treatment resulted in statistically significant increases in
cytoplasmic NRF2 levels at 6 and 24 hours, as well as significant increases in nuclear
NRF2 at 6 and 48 hour time points. The combination of DMP and Tebufenozide
treatments resulted in a statistically significant increase in cytoplasmic NRF2 levels at 48
hours post-treatment as well as a significant increase in nuclear NRF2 at the 24 hour time
point (Figure 8).
PRX1 protein levels did not exhibit significant variation in untreated control samples and
underwent a statistically significant decline in Tebufenozide-treated cells at the 48 hour
time point (Figure 9A). DMP treatment resulted in significant increases in PRX1 protein
levels at the 24 and 48 hour time points, while the combination of DMP + Tebufenozide
treatments resulted in a statistically significant increase in PRX1 protein at 48 hours posttreatment (Figure 9A). In addition, the oxidation state of PRX1 was also measured using
an antibody that recognizes both irreversibly oxidized species of the protein (PRX1-SO23;

Figure 9B). The oxidatively-inactivated PRX1-SO2-3 species underwent a statistically

significant increase in untreated control samples, while DMP, Tebufenozide and DMP +
Tebufenozide treatments did not result in any significant changes (Figure 9B). However,
because the PRX1 antibody does not differentiate between catalytically active PRX1-SH
and catalytically inactive PRX1-SO2-3, it was necessary to calculate the ratio of oxidized
PRX1-SO2-3:total PRX1 detected in Figure 9A in order to evaluate the proportion of
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PRX1 protein that was functionally active (Figure 9C). The ratio of PRX1-SO2-3: total
PRX1 increased to a statistically significant level by the 48 hour time point in untreated
control samples, which is likely a reflection of the increased density of cells following 2
days of culture. However, following induction of mHtt with Tebufenozide treatment, this
ratio increased significantly by 6 hours and remained so through the 24 and 48 hour time
points (Figure 9C). In contrast, DMP treatment resulted in statistically significant
decreases in the ratio of PRX1-SO2-3: total PRX1 at 6, 24 and 48 hour time points, while
the combination of DMP + Tebufenozide treatments resulted in modest decreases in this
ratio, reaching significance by the 48 hour time point (Figure 9C).

3.5 ARE-Luciferase Activity is Affected by DMP exposure and mHTT
expression
In order to definitively establish whether the neuroprotective effect of DMP treatment is
mediated by activation of NRF2 or some alternative mechanism, an ARE-specific
luciferase reporter contstruct was transfected into PC12-103Q-GFP cells along with a
control Rinella luciferase construct. Relative ARE-luciferase activity was determined by
calculating

the

ratio

of

ARE-luciferase

bioluminescence:Rinella

luciferase

bioluminescence to control for variable transfection efficiency. Relative ARE-luciferase
activity in untreated control cells remained uniform and unchanged while Tebufenozidetreated cells underwent statistically significant increases at 24, 48 and 72 hour time
points, peaking at 2.7 fold increased activity (Figure 10). DMP treatment resulted in
dramatic and statistically significant increases in relative ARE-luciferase activity at 24,
48 and 72 hour time points, peaking at 12.9 fold increased activity (Figure 10). DMP +
Tebufenozide treatment also resulted in statistically significant gains in relative AREluciferase activity at 24, 48 and 72 hour time points, peaking at 11.2 fold increased
activity.

As a positive control, cells were treated with 200 µM H2O2 for two hours

leading to a 14.9 fold increase in relative ARE-luciferase activity (Figure 10).
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Figure 7. Western Blot Analysis. PC12-103Q-GFP cells were untreated (A) or exposed
to Tebufenozide (B), DMP (C) or DMP + Tebufenozide (D) for 0, 6, 24 and 48 hours. At
each time point, cells were harvested and fractionated into cytosolic and nuclear extracts.
NRF2 subcellular localization was evaluated to measure NRF2 activity. PRX1 and
PRX1-SO2-3, levels were analyzed to understand how PRX1 protein levels and oxidation
state change in response to the treatments above. mHtt expression was assessed using an
anti-GFP antibody, while histone H3 was used as a nuclear loading control and actin was
used as a cytoplasmic loading control. The Prx-SO2-3 blot reveals two bands, the upper
band is Prx2-SO2-3 and the lower band is Prx1-SO2-3.
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Figure 8. Analysis of NRF2 Protein Levels and Subcellular Localization. Densiometric
analysis of immunoblots of fractionated cytoplasmic and nuclear extracts revealed that
NRF2 protein levels significantly increased in the cytoplasm with Tebufenozide
treatment and both in the cytoplasmic and nuclear compartments with DMP treatment.
The combination of DMP and Tebufenozide administration also results in statistically
significant increases in the cytoplasmic and nuclear localization of NRF2 relative to
untreated cells. Each time point was compared relative to the 0H control and no betweentreatment comparisons were made (*, P<0.05; **, P<0.01, n=3).
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Figure 9. Analysis of PRX1 Protein Levels and Oxidation State. Densiometric analysis
of PRX1 protein levels demonstrated a statistically significant decrease in PRX1 protein
levels 48 hours following Tebufenozide treatment, and statistically significant increases
in PRX1 protein at 24 and 48 hours following DMP treatment compared to untreated
cells (A). The combination of DMP and Tebufenozide resulted in a significant increase in
PRX1 protein at 48 hours post-treatment (Figure 9A). Untreated control cells underwent a
statistically significant increase in oxidized PRX1-SO2-3 at the 48 hour time point, while
DMP, Tebufenozide and DMP + Tebufenozide treatments did not result in statistically
significant changes in PRX1-SO2-3 levels (B). Since the PRX1 antibody does not
discriminate between catalytically active PRX1-SH and catalytically inactive PRX1-SO23, levels

of oxidized PRX1-SO2-3 were expressed as a ratio of total PRX1 in order to gauge

the relative proportion of inactive:active PRX1 protein (C). Each time point was
compared relative to the 0H control and no between-treatment comparisons were made (
*, P<0.05; **, P<0.01, n=3).
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Figure 10. ARE-Luciferase reporter assay. PC12-103Q-GFP cells were transfected with
the ARE-luciferase reporter plasmid and a Rinella luciferase control plasmid at a 10:1
molar ratio and relative ARE-luciferase bioluminescence was quantified by comparing
the ratio of ARE:Rinella luciferase activity. Tebufenozide, DMP and DMP +
Tebufenozide treated cells each underwent statistically significant increases in relative
ARE-luciferase activity at 24, 48 and 72 hours post-treatment. Positive control cells were
treated with 200 µM H2O2 for two hours. Each time point was compared relative to the
0H control and no between-treatment comparisons were made (*, P<0.05; **, P<0.01,
n=3).
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Chapter 4
Discussion and Future Research
4.1 Overview
In this study I sought to determine the extent to which DMP attenuates mHTT toxicity
and the mechanism by which DMP exerts a neuroprotective effect in PC12-103Q-GFP
cells. My results demonstrate that DMP treatment results in 2.5 fold increased viability in
cells expressing mHTT-103Q. Additionally, I found that the observed neuroprotective
effect associated with DMP was mediated, at least in part, by increased NRF2
transcriptional activity resulting in augmented expression of ARE genes such as Prx1 and
HO, facilitating a more robust antioxidant defense. DMP promoted a high degree of
NRF2 nuclear translocation and transcriptional activity, and as such may serve as a useful
therapeutic tool in the treatment of HD and possibly other neurodegenerative diseases.

4.2 Maintenance of Wild-Type PRX1 Following mHtt Induction Confers
Neuroprotection
PRX1 is an important cytoplasmic antioxidant protein responsible for catalyzing the
reduction of hydrogen peroxide and alkyl hydroperoxides (Rabilloud et al. 2002).
Oxidative stress associated with mitochondrial perturbation is strongly linked to mHtt
expression and is a key contributor to the death of striatal neurons in HD patients
(Landles and Bates 2004). ROS mediated damage to cellular macromolecules, coupled
with transcriptional repression and oxidative inactivation of crucial antioxidants such as
PRX1 may contribute to a compromised antioxidant defence in mHtt expressing neurons
(Krapfenbauer et al. 2003). Cha and colleagues (2009) found that increased expression of
PRX1 conferred protection against ROS-induced apoptosis in human breast cancer cells
and Schreibelt et al. (2008) identified a similar effect in brain endothelial cells. Due to its
importance in mitigating the effects of oxidative stress resulting from mHtt expression, I
sought to determine if overexpression of wild-type PRX1 or a catalytic mutant PRX1
lacking reductase activity was capable of suppressing mHTT toxicity. Indeed,
maintenance of wild-type PRX1 protein levels, when compared to control transfected
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cells, correlated with a statistically significant increase in cell viability following
expression of mHtt. In addition, the absence of even a modest neuroprotective effect
associated with overexpression of the catalytic mutant PRX1, as compared with the
transfection control, suggests that neuroprotection attributed to wild-type PRX1 is chiefly
dependent on redox cycling of its catalytic cysteine residue.

4.3 DMP Treatment Significantly Reduces mHTT Sensitivity
NRF2 is a master transcriptional regulator of antioxidant enzymes (i.e. PRX1), phase II
detoxifying enzymes (i.e. HO) and other neuroprotective proteins (i.e. multi-drug
resistance transporters) and is tightly regulated by oxidative and electrophilic stress (He
and Ma 2010). In unstressed conditions NRF2 remains bound to KEAP1 in the cytoplasm
and is rapidly degraded (with a half-life of ~20 minutes; He and Ma 2010). However,
DMP is believed to form adducts with KEAP1 such that NRF2 is released from the
complex and translocated to the nucleus (He and Ma 2010). Interestingly, when various
NRF2 activators were tested for their ability to counter mHTT toxicity, only D3T and
DMP exhibited significant protective effects. Both these compounds are sulfur-rich,
containing two thiol groups in close relative proximity to one another; situated on
adjacent carbons in DMP while being separated by one carbon in D3T. Oltipraz is
reportedly an NRF2 activator, but did not result in significant increases in viability
following mHtt expression, even though it does possess structural similarity to D3T. The
most obvious distinction between the two compounds is the six-membered pyrazinyl ring
structure conjugated to the sulfur-containing group of Oltipraz, suggesting that steric
inhibition may play a role in limiting access to Oltipraz thiol groups while less bulky
chemicals such as DMP and D3T more readily form thiol adducts with KEAP1, resulting
in more robust activation of NRF2. The DMP structural variant 3MP, which has only one
thiol constituent and a hydroxyl group replacing the second, failed to suppress mHTT
toxicity, suggesting that two thiol groups are necessary to confer neuroprotection.
Additionally, the mitochondrial ROS-specific florescent dye Mito Tracker Red was used
to confirm that DMP its self was not conferring neuroprotection by acting as a direct
antioxidant (Pitts et al. 2012).
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4.4 DMP Increases ARE-Directed Gene Expression
That control PC12-103Q-GFP cells exhibit constant levels of ARE transcripts HO and
Prx1 while Nrf2 mRNA oscillated, likely results from the fact that NRF2 has a short halflife and is highly responsive to even transient increases in oxidative stress, which can
occur with increases in cell density during culture (Li et al. 2004). Interestingly, although
induction of mHtt with Tebufenozide causes an increase in cellular oxidative stress, by 48
hours post-treatment, the levels of all three transcripts were significantly diminished.
These data suggest that the transcriptional effects of mHtt expression override or
counteract NRF2 activation. mHTT can interact with transcriptional co-factors such as
AP-1 and SP2 that are required for normal ARE-directed gene expression (Ravache et al.
2010).

It is likely that increased apoptosis in neurons expressing mHtt is, at least

partially, a result of increased oxidative stress and transcriptional repression of ARE
genes (Landles and Bates 2004). Although DMP has never previously been demonstrated
to increase NRF2 activity in cell culture, its high affinity in vitro interaction with purified
KEAP1 suggests that this may be the case (He and Ma 2010). Indeed, by 48 hours
following DMP treatment HO and Nrf2 (which activates its own expression) mRNA
levels were both increased and by 72 hours, levels of all three transcripts significantly
increased, providing support that DMP suppresses mHTT toxicity via an NRF2/ARE
mechanism (Pitts et al. 2012). DMP treatment also prevented a loss of ARE transcripts
associated with mHtt expression, resulting in maintenance of Prx1 and Nrf2 mRNA and
significantly increased HO expression. These data provide compelling evidence that
DMP may serve a therapeutic role in sustaining ARE-directed gene expression even
when combined with mHTT-related transcriptional insults.

4.5 DMP Increases Nuclear NRF2 Protein Levels
In this study, induction of mHtt resulted in significant accumulation of cytoplasmic, but
not nuclear NRF2, suggesting that mHTT prevents NRF2 localizing to the nucleus even
under oxidative stress. Accordingly, mHTT is known to interact with microtubule motors,
causing intracellular trafficking defects. Hence, the apparent disruption of NRF2 nuclear
translocation may partly explain transcriptional repression of ARE genes associated with
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mHtt expression (Li et al. 1998). Furthermore NRF2 trafficking deficits have been well
documented in HD-related neurodegenerative disorders such as Friedrich’s ataxia; a
trinucleotide repeat expansion disorder characterized by elevated neurotoxicity also
resulting from an inadequate antioxidant response to oxidative stress (Paupe et al. 2009).
DMP, in contrast, significantly increases cytoplasmic and nuclear NRF2 levels together;
which is potentiated by NRF2’s positive regulation of its own expression, forming a
positive feedback loop that maintains high NRF2 protein levels (He and Ma 2010).
KEAP1 is responsible for binding NRF2 and acting as an adapter for E3 ubiquitin ligase
to target the complex for degradation (He and Ma 2010). There is also evidence that
KEAP1 is able to translocate into the nucleus and remove transcriptionally active NRF2
from its ARE promoter sequences (Furukawa and Xiong 2005). Therefore, it is possible
that inhibition of KEAP1 by DMP prevents both the degradation of NRF2 in the
cytoplasm and its transcriptional inactivation in the nucleus. DMP treatment in
combination with induction of mHtt also resulted in a significant increase in both
cytoplasmic and nuclear NRF2 protein levels, indicating that the effects of DMP are
adequately robust even in the presence of high levels of mHTT.

4.6 DMP Increases PRX1 Expression and Reduces PRX1-SO2-3 Protein Levels
PRX1 is an important antioxidant protein related to cell survival, its expression levels are
elevated in numerous human cancers including mesothelioma, adenocarcinoma and
squamous carcinoma and elevated PRX1 has been implicated in chemotherapy resistance
(Kim et al. 2007). Induction of mHtt with Tebufenozide causes diminishment of PRX1
protein levels resulting from ARE transcriptional repression, in addition to increased
post-translational inactivation and degradation as indicated by significant increases in the
proportion of PRX1 in the cytoplasm that has been inactivated by irreversible oxidation.
DMP indirectly increases PRX1 expression by KEAP1 inhibition and the concomitant
activation of NRF2, while significantly reducing the relative abundance of inactivated
PRX1-SO2-3, thereby enhancing the cell’s antioxidant defense (He and Ma 2010).
Maintenance of PRX1 in a reduced (active) state is partly controlled by the enzyme
thioredoxin 1 (Trx1); an enzyme also regulated by NRF2 (Tanito et al. 2007). It is
therefore possible that DMP simultaneously activates increased expression of both PRX1
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and Trx1 to ensure and optimal antioxidant response (Tanito et al. 2007). Future studies
will evaluate this hypothesis.

4.7 DMP Increases NRF2/ARE-Luciferase Activity
Inferences regarding DMP-mediated NRF2 activation were initially made based on
indirect evidence such as nuclear NRF2 localization and increased ARE-controlled
mRNA and protein levels, so it was necessary to use an ARE-luciferase reporter assay to
definitively establish the effects of DMP and mHTT on NRF2 activity. Control cells
demonstrated uniform ARE-luciferase activity coinciding with constant levels of nuclear
NRF2 protein as well as HO and Prx1 transcript levels. Induction of mHtt expression
resulted in significant increases in ARE-luciferase activity presumably caused by
increased oxidative stress associated with mitochondrial dysfunction. Curiously, despite
these increases in ARE-luciferase activity, the nuclear NRF2 levels remained relatively
unaffected by mHtt expression while the ARE-directed transcripts HO and Prx1 in fact
undergo significant diminution. Since expression of ARE-luciferase is not attenuated in a
similar manner to that of HO and Prx1 mRNA, these data suggest that specific
interactions between mHTT and other transcriptional cofactors such as SP1 or AP2 may
have a more potent effect on HO and Prx1 expression than global transcriptional
repression associated with HD (Ravache et al. 2010).

In contrast, DMP treatment

increased ARE-luciferase activity to a much more dramatic extent, maintaining a >10
fold rise in activity throughout the course of the experiment, demonstrating a robust and
NRF2-specific mechanism by which DMP exerts neuroprotection. DMP treatment alone
or coupled with mHtt expression caused significantly increased ARE-luciferase activity
comparable to the H2O2 positive control, indicative of profoundly increased ARE
transcriptional activity, presumably mediated by NRF2. Although DMP potentiated
activation of ARE elements, this finding does not preclude the possibility of DMP
activating other ARE-associated transcription factors. To date, no other transcription
factors that directly bind and activate the ARE have been identified, strongly suggesting
that DMP is exerting its effect via NRF2.

4.8 Conclusions and Future Directions
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The neuroprotective properties of DMP in a HD context have previously been reported by
Aitken et al. (2004) and have since been confirmed in this study. HD neurotoxicity is
caused in part by oxidative stress combined with a compromised antioxidant defense.
Accordingly, I have identified significant reductions in ARE-directed transcript levels as
well as relative reductions in PRX1 protein levels (Landles and Bates 2004). Functional
maintenance of wild-type PRX1 protein contributes to the neuroprotective role of DMP,
as ectopic expression of PRX1 increases cell viability and DMP promotes increased
PRX1 transcription and protein levels while preventing catalytic inactivation of the
enzyme by oxidation. The mechanism by which DMP increases Prx1 mRNA and protein
levels was identified as NRF2 activation, confirmed by augmented ARE-directed gene
expression, increased nuclear localization of NRF2 and dramatically enhanced AREluciferase reporter activity. To further support these findings, a constitutively active form
of NRF2 NRF2 could be overexpressed in PC12-Htt-103Q-GFP cells to determine if this
protein alone confers protection against mHTT toxicity. Conversely, experimental
knockdown of Prx1 followed by DMP treatment would help to establish the extent to
which DMP’s neuroprotection is dependent on PRX1. Likewise NRF2 knockdown
should be carried out with DMP treatment to determine if DMP exerts a protective effect
in the absence of NRF2. Persistence of neuroprotection with knockdown of NRF2 may
indicate that DMP itself acts as either an antioxidant or affects other protective pathways.
Regardless of the exact mechanism, the ability of DMP to suppress mHTT toxicity and
maintain a robust antioxidant response, indicates that this compound is worthy of future
investigation as a potential therapy for prolonging the lifespan of HD-affected neurons
and delaying onset of HD in presymptomatic patients.
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